Companies › SpectraCure
1 active drug program in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Verteporfin Photosensitizer for photodynamic therapy | – | Phase 1 | Recurrent Prostate Cancer; Prostate Cancer; Surgical Scar; Malignant Solid Neoplasm | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03067051 | Verteporfin | Phase 1 | Recurrent Prostate Cancer | Oncology | Jul 2027 |
| NCT06807359 | Verteporfin | Phase 1 | Prostate Cancer | Oncology | Jan 2028 |
| NCT07488988 | Verteporfin | Phase 2 | Surgical Scar | Other | Aug 2028 |
| NCT06306638 | Verteporfin | Phase 1 | Malignant Solid Neoplasm | Oncology | Oct 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.